Compare Baidu Inc (BIDU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs BIO-TECHNE Corp — how do they compare? Baidu Inc trades at $106.09 (market cap $37.11B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Baidu Inc is far larger — about 3.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.
| BIDU | TECH | |
|---|---|---|
Market Cap | $37.11B | $11.24B |
Sector | Media | Health |
52-Week High | $162.52 | $72.29 |
52-Week Low | $85.99 | $43.31 |
Enterprise Value | $33.74B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $109.71, up 0.35% on the day, with a neutral technical signal and bearish moving averages. Recent earnings show a Q1 2026 miss after two prior beats, while revenue declined to $129.08B in 2025. The stock is supported by strong analyst consensus (75% buy ratings) and a $169.80 price target, but faces headwinds from negative operating cash flow and competitive pressures in AI and advertising.
The outlook hinges on AI monetization and Q2 2026 results due August 18. Upside exists if Baidu leverages partnerships with Apple and Lyft, but risks include margin compression and regulatory scrutiny in China. Valuation metrics like P/E of 78.19 suggest high expectations, making execution critical for near-term performance.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
